Enveric Biosciences (ENVB) Competitors $1.47 -0.13 (-8.13%) Closing price 03/28/2025 04:00 PM EasternExtended Trading$1.44 -0.03 (-2.04%) As of 03/28/2025 07:43 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrendsBuy This Stock ENVB vs. VRPX, PRTG, SONN, VRAX, ALLR, CDT, IMCC, RDHL, APVO, and SPRCShould you be buying Enveric Biosciences stock or one of its competitors? The main competitors of Enveric Biosciences include Virpax Pharmaceuticals (VRPX), Portage Biotech (PRTG), Sonnet BioTherapeutics (SONN), Virax Biolabs Group (VRAX), Allarity Therapeutics (ALLR), Conduit Pharmaceuticals (CDT), IM Cannabis (IMCC), RedHill Biopharma (RDHL), Aptevo Therapeutics (APVO), and SciSparc (SPRC). These companies are all part of the "pharmaceutical products" industry. Enveric Biosciences vs. Virpax Pharmaceuticals Portage Biotech Sonnet BioTherapeutics Virax Biolabs Group Allarity Therapeutics Conduit Pharmaceuticals IM Cannabis RedHill Biopharma Aptevo Therapeutics SciSparc Enveric Biosciences (NASDAQ:ENVB) and Virpax Pharmaceuticals (NASDAQ:VRPX) are both small-cap medical companies, but which is the superior stock? We will compare the two companies based on the strength of their earnings, risk, community ranking, profitability, media sentiment, valuation, analyst recommendations, dividends and institutional ownership. Is ENVB or VRPX more profitable? Enveric Biosciences' return on equity of -221.54% beat Virpax Pharmaceuticals' return on equity.Company Net Margins Return on Equity Return on Assets Enveric BiosciencesN/A -221.54% -164.32% Virpax Pharmaceuticals N/A -1,554.34%-338.29% Do analysts recommend ENVB or VRPX? Enveric Biosciences presently has a consensus price target of $10.00, suggesting a potential upside of 580.27%. Virpax Pharmaceuticals has a consensus price target of $75.00, suggesting a potential upside of 5,497.01%. Given Virpax Pharmaceuticals' higher probable upside, analysts clearly believe Virpax Pharmaceuticals is more favorable than Enveric Biosciences.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Enveric Biosciences 0 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 3.00Virpax Pharmaceuticals 0 Sell rating(s) 1 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 2.00 Which has better earnings & valuation, ENVB or VRPX? CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioEnveric BiosciencesN/AN/A-$17.29M-$38.38-0.04Virpax PharmaceuticalsN/AN/A-$15.19MN/AN/A Does the media prefer ENVB or VRPX? In the previous week, Enveric Biosciences had 1 more articles in the media than Virpax Pharmaceuticals. MarketBeat recorded 2 mentions for Enveric Biosciences and 1 mentions for Virpax Pharmaceuticals. Enveric Biosciences' average media sentiment score of 1.44 beat Virpax Pharmaceuticals' score of 0.62 indicating that Enveric Biosciences is being referred to more favorably in the media. Company Overall Sentiment Enveric Biosciences Positive Virpax Pharmaceuticals Positive Do insiders & institutionals believe in ENVB or VRPX? 13.8% of Enveric Biosciences shares are held by institutional investors. Comparatively, 32.2% of Virpax Pharmaceuticals shares are held by institutional investors. 3.2% of Enveric Biosciences shares are held by insiders. Comparatively, 3.7% of Virpax Pharmaceuticals shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term. Does the MarketBeat Community favor ENVB or VRPX? Enveric Biosciences received 3 more outperform votes than Virpax Pharmaceuticals when rated by MarketBeat users. CompanyUnderperformOutperformEnveric BiosciencesOutperform Votes660.00% Underperform Votes440.00% Virpax PharmaceuticalsOutperform Votes360.00% Underperform Votes240.00% Which has more risk and volatility, ENVB or VRPX? Enveric Biosciences has a beta of 0.47, suggesting that its stock price is 53% less volatile than the S&P 500. Comparatively, Virpax Pharmaceuticals has a beta of 0.96, suggesting that its stock price is 4% less volatile than the S&P 500. SummaryEnveric Biosciences beats Virpax Pharmaceuticals on 7 of the 12 factors compared between the two stocks. Remove Ads Get Enveric Biosciences News Delivered to You Automatically Sign up to receive the latest news and ratings for ENVB and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart ENVB vs. The Competition Export to ExcelMetricEnveric BiosciencesPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$997,000.00$6.91B$5.63B$7.83BDividend YieldN/A2.73%4.57%4.01%P/E Ratio-0.047.1723.3318.67Price / SalesN/A220.47388.4691.01Price / CashN/A65.6738.1634.64Price / Book0.146.396.894.23Net Income-$17.29M$142.12M$3.20B$247.15M7 Day Performance-15.52%-5.06%-2.98%-2.17%1 Month Performance-47.50%-7.49%1.63%-5.68%1 Year Performance-90.20%-10.91%9.44%-0.74% Enveric Biosciences Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)ENVBEnveric Biosciences3.0512 of 5 stars$1.47-8.1%$10.00+580.3%-90.2%$997,000.00N/A-0.0420Upcoming EarningsShort Interest ↓Positive NewsVRPXVirpax Pharmaceuticals2.1123 of 5 stars$0.17+1.5%$3.00+1,675.1%-98.7%$4.49MN/A0.007Gap DownPRTGPortage Biotech1.0398 of 5 stars$4.25+1.0%N/A-14.8%$4.46MN/A-0.106Upcoming EarningsShort Interest ↓News CoverageGap UpSONNSonnet BioTherapeutics2.7374 of 5 stars$1.39+1.8%$20.00+1,338.8%-29.6%$4.26M$1M0.0010Analyst ForecastShort Interest ↓VRAXVirax Biolabs Group1.6786 of 5 stars$1.28-6.6%N/A+61.8%$4.14M$84,872.000.005Short Interest ↓Gap UpALLRAllarity Therapeutics0.6855 of 5 stars$0.93-3.2%N/A-99.4%$4.12MN/A0.0010Short Interest ↓Gap UpCDTConduit PharmaceuticalsN/A$1.11+1.8%N/A-99.8%$4.04MN/A0.003Earnings ReportShort Interest ↑Positive NewsIMCCIM Cannabis1.4786 of 5 stars$1.79+0.3%N/A-42.1%$3.99M$51.39M-0.52340Upcoming EarningsShort Interest ↓News CoverageRDHLRedHill Biopharma0.5013 of 5 stars$3.01+17.6%N/A-99.2%$3.86M$3.71M0.00210Analyst ForecastShort Interest ↑Gap DownAPVOAptevo Therapeutics2.2043 of 5 stars$2.64+9.5%$10,952.00+414,748.5%-100.0%$3.85M$3.11M0.0050Short Interest ↑Gap DownSPRCSciSparc0.3546 of 5 stars$0.37-1.1%N/A-82.6%$3.84M$1.75M0.004Short Interest ↑Gap Down Remove Ads Related Companies and Tools Related Companies VRPX Alternatives PRTG Alternatives SONN Alternatives VRAX Alternatives ALLR Alternatives CDT Alternatives IMCC Alternatives RDHL Alternatives APVO Alternatives SPRC Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:ENVB) was last updated on 3/29/2025 by MarketBeat.com Staff From Our PartnersA market crash is coming—here’s whenThe stock market cycle I've used to identify the most likely day of the next market crash is the exact same in...Chaikin Analytics | SponsoredYour Wealth is Under AttackPlease don't wait—this is your moment to take action. Download your Wealth Protection Guide now, claim your fr...American Alternative | SponsoredA brutally honest economic warning for 2025 (see proof)New York Times best-selling financial author and world-renowned economist Addison Wiggin (a man who’s worked s...Banyan Hill Publishing | Sponsored$2 Trillion Disappears Because of Fed's Secretive New Move$2 trillion has disappeared from the US government's books. The reason why is a new, secretive move being c...Stansberry Research | SponsoredHas Trump finally met his match?Dylan Jovine predicted the 2008 crash over a year before it happened. Folks who listened to him had the chance...Behind the Markets | SponsoredCollect $7k per month from Tesla’s SECRET dividendTesla doesn't pay a traditional dividend.... But I just discovered a secret backdoor to collect a secret 69...Investors Alley | SponsoredEx CIA predicts 40% “double crash” – April 11The scientists here don’t study deadly viruses… directed energy weapons… or even weather control technology… ...Paradigm Press | SponsoredJust Revealed: The chip company making AI look primitiveIn his just-released video presentation, this renowned market strategist — who's been called "one of the most ...InvestorPlace | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Enveric Biosciences, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Enveric Biosciences With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Buy ENVB Stock Free ENVB Stock Alerts